Vaxcyte — Key Risks
The Company Has No Revenue, Is Burning Cash Fast, and Needs More Money Soon
The company has never sold a product and lost $766.6 million in fiscal year 2025 alone, bringing its total accumulated deficit to $2.2 billion. While it currently holds $2.4 billion in cash, it acknowledges this may only last 12 months from the filing date, and it will need to raise "substantial additional capital" beyond that to finish development and commercialization. Every future fundraise risks diluting existing shareholders or coming with unfavorable terms.
Everything Depends on VAX-31 and VAX-24 — and Neither Is Approved Yet
The company openly states that its entire business hinges on its pneumococcal conjugate vaccine (PCV) candidates, VAX-31 and VAX-24. These are still in clinical trials, and positive early results do not guarantee success in the larger Phase 3 pivotal studies required for FDA approval. If either candidate fails on safety or effectiveness grounds, or faces unexpected manufacturing delays, the company's entire pipeline is at risk — since all candidates share the same underlying manufacturing platform.
Competing Against Pfizer and Merck Is a Steep Uphill Battle
The PCV market is dominated by companies with vastly more resources. Pfizer and Merck already have approved PCVs on the market and are actively developing next-generation candidates with 25 and 30+ antigens. The company has no established sales force, no distribution network, and no track record of commercializing a product — disadvantages that become critical if and when it reaches the market.
The Manufacturing Technology Has Never Been FDA-Approved Before
The company uses a cell-free protein synthesis platform (a method of making vaccine components without living cells) licensed from Sutro Biopharma. No product made on this type of platform has ever received FDA approval, which means the regulatory pathway for manufacturing is genuinely uncharted. Past manufacturing problems at partner Lonza have already caused delays, and future issues could push timelines back further or prevent approval entirely.
ACIP Recommendation Is as Important as FDA Approval — and Not Guaranteed
Even if the FDA approves a vaccine, physicians and insurers largely follow recommendations from the Advisory Committee on Immunization Practices (ACIP), a CDC advisory body. Vaccines that receive a preferred ACIP recommendation see near-universal adoption; those that don't can struggle commercially. Recent political changes to federal vaccine policy have introduced new uncertainty about how ACIP recommendations translate into insurance coverage and reimbursement, potentially limiting the commercial value of any approval the company obtains.
A Stricter FDA Non-Inferiority Bar Raises the Approval Hurdle
For its key VAX-31 adult Phase 3 trial, the FDA required a non-inferiority threshold of 0.667 — stricter than the 0.50 standard used to approve competing vaccines from Pfizer and Merck. This means the company must clear a higher bar to prove its vaccine is comparable, making FDA approval harder to achieve than it was for rivals.
Potential Tariffs on Pharmaceutical Ingredients Could Raise Costs
The company relies on manufacturing partners with global operations, including Lonza in Switzerland, whose agreements are denominated in Swiss Francs. An active U.S. government investigation under trade law could result in new tariffs on pharmaceutical ingredients. Since the company has no commercial products to pass costs onto customers, it would have to absorb any cost increases directly.